IPCA Laboratories Limited Company Profile - Aug 19, 2011 by WrightReports

VIEWS: 142 PAGES: 10

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   IPCA Laboratories Limited
                                                                                           440 Wheelers Farms Road
                                                                                           Milford, CT 06461 U.S.A.

  Figures in Indian Rupees

                                 Wright Quality Rating:CBA20                                 Key Data

   IPCA Laboratories Limited is an India-based pharmaceutical company with a thrust          Ticker:
   on exports. The Company's formulations business in India consists of 13 marketing         524494
   divisions focusing on therapeutic segments, including two new divisions: Ipca Pain
   Management and Ipca Dynamix, which started operations from April 2011. As of              2011 Sales:
   March 31, 2011, the Company's top 10 brand included Zerodol (Aceclofenac &
   Combinations), Lariago (Chloroquine), HCQS (Hydroxychloroquine), Perinorm
   (Metoclopramide), Rapither (Artemotil), Tenoric (Chlorthalidone + Atenolol), Lumerax
   (Artemether + Lumefantrine), Etova (Etodolac), Malirid (Primaquine) and Folitrax          Major Industry:
   (Methotrexate). The dosage forms include tablets, capsules, oral liquids, dry             Drugs, Cosmetics & Health
   powders for suspension, and injectables (liquid & dry).                                   Care
                       Stock Chart                                Officers
                                                           Non Executive Chairman            Sub Industry:
                                                                 R. S. Hugar                 Ethical Drug Manufacturers

                                                         Executive Managing Director Country:
                                                          & Chief Executive Officer  India
                                                              Premchand Godha
                                                               Chief Financial Officer &     Indian Rupees
                                                                 Managing Director
                                                                   Ashok Kumar Jain
                                                                                             Fiscal Year Ends:



                                                                                             Share Type:
           Stock Price (8/12/2011): 318.95                                                   Equity
              Recent stock performance
                  1 Week      -2.8%
                                                                                             Market Capitalization:
                  4 Weeks     -5.9%
                  13 Weeks     7.5%
To top